next generation immune checkpoint modulators for the treatment of multiple disease indications

Roots_Analysis's picture

Over time, significant strides have been made in immune checkpoint research, resulting in the discovery of several inhibitory (LAG-3, TIM-3, TIGIT, VISTA and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB and CD40), which are being investigated as potential targets for therapy development. Further, studies of combinatorial immune checkpoint blockade / co-stimulation, targeting newly identified checkpoints along with known checkpoint inhibitor therapies, have demonstrated promising clinical outcomes as well.


To order this 350+ page report, which features 140+ figures and 170+ tables, please visit this link


The USD 12 billion (by 2030) financial opportunity within the next generation immune checkpoint modulators market has been analyzed across the following segments:

Target Disease Indication 

  • Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Colorectal Cancer
  • Head and Neck Cancer
  • Lung Cancer
  • Lupus Nephritis
  • Melanoma
  • Multiple Myeloma
  • Primary Sjögren's Syndrome
  • Others 


Target Immune Checkpoint

  • B7-H3
  • CD38
  • CD40
  • CD47
  • Others


Mechanism of Action

  • Inhibitory
  • Stimulatory


Therapeutic Modality

  • Monoclonal Antibody
  • Small Molecule


Type of Therapy 

  • Monotherapy 
  • Combination Therapy


Route of Administration

  • Intravenous
  • Subcutaneous
  • Others


Key Geographical Regions 

  • North America
  • Europe
  • Asia-Pacific and the Rest of the World 


The Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030report features the following companies, which we identified to be key players in this domain:

Bristol Myers Squibb




Trillium Therapeutics


Table of Contents


1. Preface

2. Executive Summary

3. Introduction

4. Current Market Landscape: Clinical and Preclinical Molecules

5. Market Landscape: Therapies Targeting Cd47

6. Market Landscape: Therapies Targeting 4-1bb

7. Clinical Trial Analysis 

8. Company Profiles: Next Generation Inhibitors and Stimulators

9. Academic Grants Analysis

10. Partnerships and Collaborations

11. Target Competitiveness Analysis

12. Big Pharma Initiatives

13. Market Forecast and Opportunity Analysis

14. Concluding Remarks


15. Executive Insights


16. Appendix 1: Tabulated Data


17. Appendix 2: List of Companies and Organizations


To purchase a copy, please visit


Contact Details

Gaurav Chaudhary

+1 (415) 800 3415